Compare RBCAA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | ZYME |
|---|---|---|
| Founded | 1974 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1998 | 2022 |
| Metric | RBCAA | ZYME |
|---|---|---|
| Price | $91.80 | $25.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $41.23 |
| AVG Volume (30 Days) | 83.0K | ★ 494.2K |
| Earning Date | 10-16-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $186.92 |
| Revenue Next Year | $3.20 | $16.24 |
| P/E Ratio | $119.77 | ★ N/A |
| Revenue Growth | 8.50 | ★ 38.87 |
| 52 Week Low | $63.97 | $16.00 |
| 52 Week High | $102.22 | $31.34 |
| Indicator | RBCAA | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 32.16 | 47.17 |
| Support Level | $88.24 | $22.10 |
| Resistance Level | $93.54 | $27.30 |
| Average True Range (ATR) | 1.60 | 1.09 |
| MACD | -0.42 | -0.14 |
| Stochastic Oscillator | 5.68 | 33.08 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.